

A U T H O R I N D E X

- A**hmed, N. 83–95
 Ajamieh, H. 83–95
 Al Awar, R. 405–411
 Alba, J. S. 83–95
 Aldama, A. 83–95
 Alonso-Orgaz, S. 457–463
 Altavilla, D. 389–395
 Anderson, G. L. 117–123
 Anderson, S. I. 303–309
 Arrigo, F. 389–395
 Astley, S. B. 189–197
 Aurell, M. 311–317
 Azar, S. 405–411
 Aznaouridis, K. A. 55–60
- B**aggio, B. 177–182
 Balsam, L. B. 483–492
 Bartkowiak, G. 397–403
 Bastiaanse, J. 117–123
 Bavanandan, S. 75–82
 Beckmann, M. W. 209–215
 Bellingier, L. 413–420
 Bergström, G. 325–334
 Berlanga, J. 83–95
 Besenyey, C. 103–107
 Biaggioni, I. 161–163
 Binder, H. 209–215
 Birmingham Medical
 Research Expeditionary
 Society 319–324
 Bluck, L. J. C. 513–521
 Boeve, B. F. 343–354
 Bogert, L. W. J. 493–501
 Bonventre, J. V. 421–430
 Bradwell, A. R. 319–324
 Braschi, S. 189–197
 Braun, C. 475–481
 Brown, M. D. 303–309
 Bustin, S. A. 365–379
- C**alò, L. A. 177–182
 Cao, Y.-X. 439–446
 Caron, A. 97–102
 Carr, S. J. 75–82
 Carrasco, C. 457–463
 Cascorbi, I. 475–481
- Chan, C. W. M. 319–324
 Chang, N.-C. 267–276
 Chao, T.-H. 39–43
 Chaudhuri, N. 125–133
 Chen, J.-H. 39–43
 Cherry, L. 171–176
 Chew Jr, H. G. 277–286
 Cibrian, D. 83–95
 Clapperton, A. T. 513–521
 Coward, W. A. 513–521
 Cripps, R. L. 1–11
 Crisafulli, A. 389–395
 Culver, B. 277–286
 Cunningham, G. A.
 447–455
- D**'Anneo, G. 389–395
 Daroszevska, A. 257–263
 Davenport, A. 335–342
 Davidson, B. R. 465–473
 Davis, M. E. 381–388
 Diedrich, A. 161–163
 Dittrich, R. 209–215
 Divecha, H. 171–176
 Dong, F. 277–286
 Dower, S. K. 125–133
 Dupuis, J. 97–102
 Dziarmaga, M. 397–403
- E**ames, P. J. 109–115
 Easter, M. J. 45–54
 Edvinsson, L. 335–342
 Erol-Yilmaz, A. 493–501
- F**entum, B. 75–82
 Fernandez-Tagarro, M.
 199–207
 Ferro, A. 439–446
 Fischer, J. E. 61–67
 Flatt, P. R. 447–455
 Frampton, C. M. 381–388
 Freyre, F. 83–95
 Fusai, G. 465–473
- G**an, L.-m. 325–334
 García-Méndez, A. 457–463
- Glantzounis, G. K. 465–473
 Goecke, T. 209–215
 Gonzalez-San Martin, F.
 199–207
 Gordon, M. Y. 13–25
 Grabe, H. J. 475–481
 Grönros, J. 325–334
 Guermouche, B. 287–295
 Guillén, I. 83–95
 Gulati, R. 27–37
 Guzik, P. 397–403
- H**afez, T. 465–473
 Hägg, U. 325–334
 Hanebuth, D. 61–67
 Healy, D. G. 355–364
 Herlitz, H. 311–317
 Hichami, A. 287–295
 Higashikata, T. 183–188
 Hirowatari, Y. 297–302
 Hoar, H. 319–324
 Hoffmann, I. 209–215
 Holst, D. P. 523–530
 Hothorn, T. 209–215
 Hsu, S. I. 421–430
 Huang, Y.-Y. 39–43
 Hwalla, N. 405–411
- I**maizumi, A. 503–511
 Imray, C. H. E. 319–324
 Inazu, A. 183–188
- J**ain, S. 355–364
 Ji, Y. 439–446
 Jimenez, F. 199–207
 John, U. 475–481
 Johns, E. J. 503–511
 Jonsdottir, I. H. 325–334
- K**anagy, N. L. 431–437
 Kanoria, S. 465–473
 Karatzi, K. N. 55–60
 Karatzis, E. N. 55–60
 Kąsinowski, R. 397–403
 Katsuda, S. 183–188
- Kawashiri, M. 183–188
 Kaye, D. M. 523–530
 Kelley, R. O. 277–286
 Khan, N. A. 287–295
 Kobayashi, J. 183–188
 Kohsaka, T. 503–511
 Koizumi, J. 183–188
 Kollai, M. 103–107
 Kon, M. 117–123
 Krauze, T. 397–403
 Kudielka, B. M. 61–67
 Kumar, S. 243–256
 Kurosawa, H. 297–302
 Kusminski, C. M. 243–256
- L**ainchbury, J. G. 381–388
 Langley-Evans, S. C.
 413–420
 Lee, T.-M. 267–276
 Lekakis, J. P. 55–60
 Lénárd, Z. 103–107
 Lerman, A. 27–37
 Li, Y.-H. 39–43
 Lin, C.-C. 39–43
 Lin, M.-S. 267–276
 Longmore, J. 335–342
 López Farré, A. J. 457–463
 Lopez-Saura, P. 83–95
 Lowe, G. D. O. 171–176
 Lucà, F. 389–395
 Lüdemann, J. 475–481
- M**abuchi, H. 183–188
 Macaya, C. 457–463
 Macias, R. I. R. 199–207
 Malik, J. 165–170
 Malmjö, M. 335–342
 Maltaris, T. 209–215
 Marin, J. J. G. 199–207
 Marley, S. B. 13–25
 Marshall, J. M. 45–54
 Martin-Gronert, M. S. 1–11
 Marwick, T. H. 265–266
 Mavrikakis, M. E. 55–60
 McClenaghan, N. H.
 447–455

- McTernan, P. G. 243–256
Melenovsky, V. 165–170
Merino, N. 83–95
Mersich, B. 103–107
Merzouk, H. 287–295
Micari, A. 389–395
Mioni, C. 389–395
Miwa, K. 183–188
Molero, L. 457–463
Monte, M. J. 199–207
Montequin, J. F. 83–95
Moutairou, K. 287–295
Mueller, A. 209–215
Mueller, R. 365–379
Musacchio, E. 177–182
- N**
Nakamura, A. 503–511
Newsholme, P. 447–455
Ng, L. 75–82
Nicholls, M. G. 381–388
Niimi, R. 503–511
Nohara, A. 183–188
- O**
Obeid, O. 405–411
Omland, T. 69–74
oude Egbrink, M. G. A.
117–123
Ozanne, S. E. 1–11
- P**
Pagnin, E. 177–182
Palmgren, E. 311–317
Panerai, R. B. 109–115
Papamichael, C. M. 55–60
Parkes, H. 465–473
- Parnell, M. M. 523–530
Passaniti, M. 389–395
Pattinson, K. 319–324
Pemberton, C. J. 381–388
Polosa, R. 135–142
Popowski, K. 475–481
Potter, J. F. 109–115
Preckel, D. 61–67
Priante, G. 177–182
- Q**
Quaglia, A. 465–473
Quintela, A. M. 83–95
- R**
Rademaker, M. T. 381–388
Raffa, S. 389–395
Raj, S. R. 161–163
Ralston, S. H. 257–263
Ray, R. 217–226
Ren, J. 277–286
Richards, A. M. 381–388
Rigó Jr, J. 103–107
Robbins, R. C. 483–492
Ruël, N. 97–102
Rumley, A. 171–176
Russo, C. 135–142
- S**
Sabroe, I. 125–133
Saker, M. 287–295
Sampson, M. J. 189–197
Saporito, F. 389–395
Sardella, A. 389–395
Sattar, N. 171–176
Scalera, F. 209–215
Schalkwijk, C. G. 143–159
- Schild, R. L. 209–215
Schlembach, D. 209–215
Schlüter, C. 475–481
Seifalian, A. 465–473
Shah, A. M. 217–226
Sheth, H. 465–473
Shibuya, M. 227–241
Simari, R. D. 27–37
Simek, J. 165–170
Slaaf, D. W. 117–123
Soulimane-Mokhtari, N. A.
287–295
Squadrito, F. 389–395
Stamatelopoulos, K. S.
55–60
Stehouwer, C. D. A.
143–159
Studinger, P. 103–107
Sturrock, R. 171–176
Svacina, S. 165–170
Svobodova, J. 165–170
- T**
Tada, N. 297–302
Takahashi, H. 227–241
Takata, M. 183–188
Thornalley, P. J. 83–95
Triana, M. E. 83–95
Tsai, C.-H. 267–276
Tsai, W.-C. 39–43
Tukkie, R. 493–501
- U**
Uddman, E. 335–342
Urquiza, D. 83–95
- V**
Vamvakou, G. 55–60
van der Heijden, B. E. P. A.
117–123
Van Lieshout, J. J. 493–501
Vidal Jr, B. C. 421–430
Vik-Mo, H. 69–74
Vink, H. 117–123
Völzke, H. 475–481
von Känel, R. 61–67
- W**
Wackenfors, A. 335–342
Wesseling, K. H. 397–403
Whyte, M. K. B. 125–133
Wichterle, D. 165–170
Widgren, B. 311–317
Wikström, J. 325–334
Willis, G. 189–197
Wold Knudsen, C. 69–74
Wolff, B. 475–481
Wood, N. W. 355–364
Wright, A. D. 319–324
Wykretowicz, A. 397–403
Wysock, H. 397–403
- X**
Xu, B. 439–446
- Y**
Yanagawa, Y. 503–511
Yandle, T. G. 381–388
Yang, W. 465–473
Yao, K. 439–446
Yessoufou, A. 287–295
Yoshida, H. 297–302
- Z**
Zhang, X. 277–286

S U B J E C T I N D E X

- N-Acetylcysteine**
 hepatic steatosis, ischaemia/
 reperfusion 465–473
- Adenovirus**
 gene delivery, sepsis 503–511
- Adiponectin**
 diabetes, lipoprotein 297–302
- α_2 -Adrenergic receptor**
 hypertension, sympathetic nervous
 system 431–437
- Adrenomedullin**
 pharmacokinetics, pulmonary
 circulation 97–102
- β_2 -Adrenoceptor**
 gene delivery, renal failure 503–511
- Advanced glycation end-product
 (AGE)**
 diabetes, nitric oxide synthase
 (NOS) 439–446
- L-Alanine**
 apoptosis, pancreatic β -cell
 447–455
 endothelial function, exercise
 523–530
- Altitude**
 cerebral oxygenation,
 phosphodiesterase-5 inhibitor
 (sildenafil) 319–324
- Angiogenesis**
 inflammation, vascular endothelial
 growth factor (VEGF) 227–241
- Angioplasty**
 ischaemic preconditioning,
 inflammation 267–276
- Angiotensin II**
 hypertension, renal haemodynamics
 311–317
- Ankylosing spondylitis**
 coronary heart disease,
 inflammation 171–176
- Antioxidation**
 hypertension, transthoracic colour
 Doppler echocardiography
 265–266, 325–334
- Apoptosis**
 L-alanine, pancreatic β -cell 447–455
- Appetite**
 fetal programming, obesity 1–11
 low-protein diet, fetal programming
 413–420
- Arachidonic acid**
 nitric oxide synthase (NOS),
 osteoblast 177–182
- Arterial elasticity**
 pregnancy, stiffness 103–107
- Arterial pressure**
 endothelin, pre-eclampsia 209–215
- Arterial stiffness**
 finger arterial pressure, vasovagal
 syncope 161–163, 165–170
- Asthma**
 inflammation, tumour necrosis
 factor- α (TNF- α) 135–142
- Atherosclerosis**
 endothelial cell, vascular disease
 27–37
- ATP-binding cassette transporter**
 genetic marker, polymorphism
 183–188
- Baroreflex sensitivity**
 diabetes, endothelial function
 397–403
- Bile acid**
 hepatocarcinogenesis, liver 199–207
- Biomarker**
 proteomics, renal disease 421–430
- Bone**
 genetic susceptibility, Paget's disease
 257–263
- Caffeine**
 endothelial function, flow-mediated
 vasodilation 55–60
- Calf blood flow**
 pre-capillary resistance, venous
 congestion 303–309
- Cardiac output**
 cerebral blood velocity, pacemaker
 493–501
- Cardiac repair**
 haematopoietic stem cell, ischaemic
 heart disease 483–492
- Cardiovascular disease**
 inflammation, stress 61–67
- Carotid atherosclerosis**
 genetic polymorphism, nitric oxide
 synthase (NOS) 475–481
- Cerebral artery**
 5-hydroxytryptamine (5-HT)
 receptor, vasoconstriction
 335–342
- Cerebral autoregulation**
 ectopic heartbeat, vascular
 resistance 109–115
- Cerebral blood velocity**
 cardiac output, pacemaker 493–501
- Cerebral oxygenation**
 altitude, phosphodiesterase-5
 inhibitor (sildenafil) 319–324
- Chronic myeloid leukaemia**
 progenitor cell, stem cell 13–25
- Clinical diagnosis**
 disease, real-time reverse
 transcription PCR (qRT-PCR)
 365–379
- Coronary artery disease**
 diabetes, glucose metabolism
 397–403
 myocardial infarction,
 osteoprotegerin 389–395
- Coronary flow velocity reserve**
 exercise, hypertension 265–266,
 325–334
- Coronary heart disease**
 ankylosing spondylitis, inflammation
 171–176
- Corticotropin**
 heart failure, urocortin I 381–388
- Dementia**
 genetic basis, Lewy body 343–354
- Diabetes**
 adiponectin, lipoprotein 297–302
 advanced glycation end-product
 (AGE), nitric oxide synthase
 (NOS) 439–446
 baroreflex sensitivity, endothelial
 function 397–403

- endothelial dysfunction, vascular complication 143–159
- glucose metabolism, minimal model 513–521
- low-density lipoprotein (LDL), paraoxonase 189–197
- macrosomia, polyunsaturated fatty acid 287–295
- methylglyoxal, wound healing 83–95
- obesity, resistin 243–256
- Disease**
- clinical diagnosis, real-time reverse transcription PCR (qRT-PCR) 365–379
- Ectopic heartbeat**
- cerebral autoregulation, vascular resistance 109–115
- Endothelial cell**
- atherosclerosis, vascular disease 27–37
- Endothelial dysfunction**
- diabetes, vascular complication 143–159
- Endothelial function**
- L-arginine, exercise 523–530
- baroreflex sensitivity, diabetes 397–403
- caffeine, flow-mediated vasodilation 55–60
- NADPH oxidase, reactive oxygen species 217–226
- Endothelin**
- arterial pressure, pre-eclampsia 209–215
- Endothelium**
- Raynaud's disease, vasodilatation 45–54
- Exercise**
- L-arginine, endothelial function 523–530
- coronary flow velocity reserve, hypertension 265–266, 325–334
- Fetal programming**
- appetite, obesity 1–11
- low-protein diet, appetite 413–420
- Finger arterial pressure**
- arterial stiffness, vasovagal syncope 161–163, 165–170
- Flow-mediated vasodilation**
- caffeine, endothelial function 55–60
- hypertension, vascular endothelial growth factor (VEGF) 39–43
- Gene delivery**
- adenovirus, sepsis 503–511
- Genetic basis**
- dementia, Lewy body 343–354
- Lewy body, Parkinson's disease 355–364
- Genetic marker**
- ATP-binding cassette transporter, polymorphism 183–188
- Genetic polymorphism**
- carotid atherosclerosis, nitric oxide synthase (NOS) 475–481
- Genetic susceptibility**
- bone, Paget's disease 257–263
- Ghrelin**
- insulin, meal composition 405–411
- Glucose metabolism**
- diabetes, minimal model 513–521
- Haematopoietic stem cell**
- cardiac repair, ischaemic heart disease 483–492
- Haemoglobin**
- heart failure, natriuretic peptide 69–74
- Heart failure**
- corticotropin, urocortin I 381–388
- endothelial function, nitric oxide 523–530
- haemoglobin, natriuretic peptide 69–74
- Hepatic steatosis**
- N-acetylcysteine, ischaemia/reperfusion 465–473
- Hepatocarcinogenesis**
- bile acid, liver 199–207
- 5-Hydroxytryptamine (5-HT) receptor**
- cerebral artery, vasoconstriction 335–342
- Hypertension**
- α_2 -adrenergic receptor, sympathetic nervous system 431–437
- angiogenesis, vascular endothelial growth factor (VEGF) 227–241
- angioplasty, ischaemic preconditioning 267–276
- angiotensin II, renal haemodynamics 311–317
- ankylosing spondylitis, coronary heart disease 171–176
- asthma, tumour necrosis factor- α (TNF- α) 135–142
- cardiovascular disease, stress 61–67
- coronary flow velocity reserve, exercise 265–266, 325–334
- flow-mediated vasodilation, vascular endothelial growth factor (VEGF) 39–43
- ischaemia/reperfusion, microcirculation 117–123
- Insulin**
- ghrelin, meal composition 405–411
- Iron deficiency**
- NADPH oxidase, reactive oxygen species 277–286
- Ischaemia/reperfusion**
- N-acetylcysteine, hepatic steatosis 465–473
- hypothermia, microcirculation 117–123
- Ischaemic heart disease**
- cardiac repair, haematopoietic stem cell 483–492
- Ischaemic preconditioning**
- angioplasty, inflammation 267–276
- Kidney disease**
- natriuretic peptide, uraemia 75–82
- Lewy body**
- dementia, genetic basis 343–354
- genetic basis, Parkinson's disease 355–364
- Lipoprotein**
- adiponectin, diabetes 297–302
- Liver**
- bile acid, hepatocarcinogenesis 199–207
- Low-density lipoprotein (LDL)**
- diabetes, paraoxonase 189–197
- Low-protein diet**
- appetite, fetal programming 413–420
- Lung disease**
- pathogen, Toll-like receptor 125–133
- Macrosomia**
- diabetes, polyunsaturated fatty acid 287–295
- Meal composition**
- ghrelin, insulin 405–411
- Methylglyoxal**
- diabetes, wound healing 83–95
- Microcirculation**
- hypothermia, ischaemia/reperfusion 117–123
- Minimal model**
- diabetes, glucose metabolism 513–521
- Myocardial infarction**
- coronary artery disease, osteoprotegerin 389–395

- NADPH oxidase**
 endothelial function, reactive oxygen species 217–226
 reactive oxygen species, iron deficiency 277–286
- Natriuretic peptide**
 haemoglobin, heart failure 69–74
 kidney disease, uraemia 75–82
- Nitric oxide synthase (NOS)**
 advanced glycation end-product (AGE), diabetes 439–446
 arachidonic acid, osteoblast 177–182
 carotid atherosclerosis, genetic polymorphism 475–481
- Obesity**
 appetite, fetal programming 1–11
 diabetes, resistin 243–256
- 17 β -Oestradiol**
 proteomics, vascular smooth muscle cell 457–463
- Osteoblast**
 arachidonic acid, nitric oxide synthase (NOS) 177–182
- Osteoprotegerin**
 coronary artery disease, myocardial infarction 389–395
- Pacemaker**
 cardiac output, cerebral blood velocity 493–501
- Paget's disease**
 bone, genetic susceptibility 257–263
- Pancreatic β -cell**
 L-alanine, apoptosis 447–455
- Paraoxonase**
 diabetes, low-density lipoprotein (LDL) 189–197
- Parkinson's disease**
 Lewy body, genetic basis 355–364
- Pathogen**
 lung disease, Toll-like receptor 125–133
- Pharmacokinetics**
 adrenomedullin, pulmonary circulation 97–102
- Phosphodiesterase-5 inhibitor (sildenafil)**
 altitude, cerebral oxygenation 319–324
- Polymorphism**
 ATP-binding cassette transporter, genetic marker 183–188
- Polyunsaturated fatty acid**
 diabetes, macrosomia 287–295
- Pre-capillary resistance**
 calf blood flow, venous congestion 303–309
- Pre-eclampsia**
 arterial pressure, endothelin 209–215
- Pregnancy**
 arterial elasticity, stiffness 103–107
- Progenitor cell**
 chronic myeloid leukaemia, stem cell 13–25
- Pro-inflammatory cytokine**
 L-alanine, gene expression 447–455
- Proteomics**
 biomarker, renal disease 421–430
 17 β -oestradiol, vascular smooth muscle cell 457–463
- Pulmonary circulation**
 adrenomedullin, pharmacokinetics 97–102
- Raynaud's disease**
 endothelium, vasodilatation 45–54
- Reactive oxygen species**
 endothelial function, NADPH oxidase 217–226
 NADPH oxidase, iron deficiency 277–286
- Real-time reverse transcription PCR (qRT-PCR)**
 clinical diagnosis, disease 365–379
- Renal disease**
 biomarker, proteomics 421–430
- Renal haemodynamics**
 angiotensin II, hypertension 311–317
- Resistin**
 diabetes, obesity 243–256
- Sepsis**
 adenovirus, gene delivery 503–511
- Stem cell**
 chronic myeloid leukaemia, progenitor cell 13–25
- Stiffness**
 arterial elasticity, pregnancy 103–107
- Stress**
 cardiovascular disease, inflammation 61–67
 Sympathetic nervous system
 α_2 -adrenergic receptor, hypertension 431–437
- Toll-like receptor**
 lung disease, pathogen 125–133
- Tumour necrosis factor- α (TNF- α)**
 asthma, inflammation 135–142
- Uraemia**
 kidney disease, natriuretic peptide 75–82
- Urocortin I**
 corticotropin, heart failure 381–388
- Vascular complication**
 diabetes, endothelial dysfunction 143–159
- Vascular disease**
 atherosclerosis, endothelial cell 27–37
- Vascular endothelial growth factor (VEGF)**
 angiogenesis, inflammation 227–241
 flow-mediated vasodilatation, hypertension 39–43
- Vascular resistance**
 cerebral autoregulation, ectopic heartbeat 109–115
- Vascular smooth muscle cell**
 17 β -oestradiol, proteomics 457–463
- Vasoconstriction**
 cerebral artery, 5-hydroxytryptamine (5-HT) receptor 335–342
- Vasodilatation**
 endothelium, Raynaud's disease 45–54
- Vasovagal syncope**
 arterial stiffness, finger arterial pressure 161–163, 165–170
- Venous congestion**
 calf blood flow, pre-capillary resistance 303–309
- Wound healing**
 diabetes, methylglyoxal 83–95